证券简称：尖峰集团 证券代码：600668 编号：临 2026-007 浙江尖峰集团股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | 回购方案首次披露日 | 2025年4月22日 | | --- | --- | | 回购方案实施期限 | 自董事会审议通过本次回购股份方案之日起12个月内 | | 预计回购金额 | 2,000万元-4,000万元 | | 回购用途 | □减少注册资本 | | | √用于员工持股计划或股权激励 | | | □用于转换公司发行的可转换为股票的公司债券 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 1,926,200股 | | 累计已回购股数占总股本比例 | 0.467% | | 累计已回购金额 | 2,238.22万元 | | 实际回购价格区间 | 9.97元/股～12.27元/股 | 重要内容提示： 一、回购股份的基本情况 浙江尖峰集团股份有限公司（以下简称"公司"）于 2025 年 4 月 18 日召开 了第 ...

证券代码：600668 证券简称：尖峰集团 编号：临 2026-006 重要内容提示： 近日，浙江尖峰集团股份有限公司（以下简称"本公司"）的全资子公司浙江 尖峰药业有限公司（以下简称"尖峰药业"）收到国家药品监督管理局核准签发的 复方托吡卡胺滴眼液（0.5ml：托吡卡胺 2.5mg 与盐酸去氧肾上腺素 2.5mg）《药 品上市申请不予批准通知书》（通知书编号：2026L00157；受理号：CYHS2501293）， 现将相关情况公告如下： 一、药品的基本情况 药品名称：复方托吡卡胺滴眼液 剂型：滴眼剂 规格：0.5ml：托吡卡胺 2.5mg 与盐酸去氧肾上腺素 2.5mg 申请事项：药品注册（境内生产） 注册分类：化学药品 4 类 1 本次尖峰药业收到复方托吡卡胺滴眼液（0.5ml：托吡卡胺 2.5mg 与盐酸 去氧肾上腺素 2.5mg）《药品上市申请不予批准通知书》不会对公司当期 业绩产生重大影响。 尖峰药业多剂量复方托吡卡胺滴眼液（规格：5ml：托吡卡胺 25mg 与盐 酸去氧肾上腺素 25mg）目前仍在审评中。 风险提示：由于医药产品具有高科技、高风险、高附加值的特点，药品 的前期研发及研制、报批到投 ...

证券简称：尖峰集团 证券代码：600668 编号：临 2026-005 浙江尖峰集团股份有限公司 具体内容详见公司于 2025 年 4 月 22 日、7 月 16 日在上海证券交易所网站 （www.sse.com.cn）披露的《尖峰集团关于以集中竞价交易方式回购公司股份方 1 案的公告》（临 2025-014）、《尖峰集团关于实施 2024 年年度权益分派后调整回 购股份价格上限的公告》（临 2025-034）。 二、回购股份的进展情况 根据《上市公司股份回购规则》、《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，在回购股份期间,上市公司应当在每个月的前 三个交易日内公告截至上月末的回购进展情况。现将本次回购情况公告如下： 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | 回购方案首次披露日 | 2025年4月22日 | | --- | --- | | 回购方案实施期限 | 自董事会审议通过本次回购股份方案之日起12个月内 | | 预计回购金额 | ...

Core Viewpoint - The article discusses the performance of the A-share market, highlighting the fluctuations in major indices and the notable movements in specific sectors such as media and pharmaceuticals. Market Performance - The Shanghai Composite Index decreased by 0.02% to 4122.34, while the Shenzhen Component Index also fell by 0.02% to 14206.26. The ChiNext Index dropped by 0.14% to 3328.02, and the Sci-Tech Innovation Board Index rose by 0.19% to 1800.35 [4][12]. - The total trading volume in the Shanghai and Shenzhen markets reached 1.4 trillion yuan, with over 2800 stocks declining [6]. Sector Highlights - The media sector experienced significant gains, with multiple stocks such as Light Media and China Film hitting the daily limit, and Huace Film and Happiness Blue Sea rising over 15% [5][6]. - The innovative drug concept saw a surge, with stocks like Guangsheng Tang increasing by over 13% [6]. - The semiconductor sector also performed well, with stocks like Chipone Technology rising over 8% [10]. New Listings - Three new stocks were listed, with N Electric Technology opening at a remarkable increase of 750.05% on its first day [11]. Other Market Movements - The precious metals, shipping, and liquor sectors showed weakness, contrasting with the strong performance of the media and innovative drug sectors [5][6].

Group 1 - The company,尖峰集团, announced a share buyback program, having repurchased approximately 1.79 million shares, which represents 0.433% of its total share capital of about 413 million shares [1] - The buyback was conducted through the Shanghai Stock Exchange's centralized bidding system, with the lowest transaction price at 11.07 CNY per share and the highest at 12.27 CNY per share [1] - The total amount spent on the share buyback was approximately 20.92 million CNY [1] Group 2 - 宝利德, a major automotive sales company known for selling luxury cars like Rolls-Royce and Porsche, has entered bankruptcy liquidation, with its headquarters in Hangzhou now vacant and its subsidiary in Yiwu sealed [1]

证券简称：尖峰集团 证券代码：600668 编号：临 2026-004 浙江尖峰集团股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | 回购方案首次披露日 | 2025年4月22日 | | --- | --- | | 回购方案实施期限 | 自董事会审议通过本次回购股份方案之日起12个月内 | | 预计回购金额 | 2,000万元-4,000万元 | | 回购用途 | □减少注册资本 | | | √用于员工持股计划或股权激励 | | | □用于转换公司发行的可转换为股票的公司债券 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 1,789,200股 | | 累计已回购股数占总股本比例 | 0.433% | | 累计已回购金额 | 2,091.67万元 | | 实际回购价格区间 | 11.07元/股～12.27元/股 | 重要内容提示： 一、回购股份的基本情况 浙江尖峰集团股份有限公司（以下简称"公司"）于 2025 年 4 月 18 日召开 了 ...

Core Viewpoint - The company, Jianfeng Group, has announced a share buyback program, indicating a commitment to enhancing shareholder value through the repurchase of its own shares [1] Group 1: Share Buyback Details - As of January 31, 2026, the company has repurchased a total of 1.7892 million shares [1] - This represents 0.433% of the company's total share capital of 413 million shares [1] - The shares were bought back at a minimum price of 11.07 yuan per share and a maximum price of 12.27 yuan per share [1] - The total amount spent on the buyback is approximately 20.9167 million yuan, excluding transaction fees [1]

Core Viewpoint - The company, Jianfeng Group, has announced a share buyback program, indicating a commitment to returning value to shareholders through the repurchase of its own shares [1] Group 1: Share Buyback Details - As of January 31, 2026, the company has repurchased a total of 1.7892 million shares [1] - This represents 0.433% of the company's total share capital of 413 million shares [1] - The shares were bought back at a minimum price of 11.07 yuan per share and a maximum price of 12.27 yuan per share [1] - The total amount spent on the buyback is approximately 20.9167 million yuan, excluding transaction fees [1]

Core Viewpoint - Zhejiang Jianfeng Group Co., Ltd. anticipates a significant increase in net profit for the year 2025, while also forecasting a substantial decrease in net profit after excluding non-recurring gains [2][4]. Group 1: Performance Forecast - The company expects to achieve a net profit attributable to shareholders of approximately 460 million yuan for the year 2025, representing an increase of about 352.01 million yuan, or 325.97% compared to the previous year [2][4]. - The forecasted net profit attributable to shareholders after excluding non-recurring gains is approximately -215 million yuan, indicating a decrease of about 311.62 million yuan, or 322.53% year-on-year [2][4]. Group 2: Previous Year Performance - In the previous year, the total profit was approximately 201.20 million yuan, with a net profit attributable to shareholders of about 107.99 million yuan, and a net profit after excluding non-recurring gains of approximately 96.62 million yuan [6]. Group 3: Reasons for Performance Changes - The significant increase in net profit is primarily due to the equity method accounting for Tian Shili Biological Pharmaceutical Industry Group Co., Ltd., which sold its equity assets, resulting in substantial non-recurring gains [8]. - The decrease in net profit after excluding non-recurring gains is attributed to reduced demand in the cement industry and declining prices and sales in the pharmaceutical sector, influenced by policies such as drug procurement and price reductions [9][10].

Core Viewpoint - The company, Jianfeng Group, has announced an expected net profit of approximately 460 million yuan for the year 2025, indicating a significant increase compared to the previous year [2] Financial Performance - The projected net profit for 2025 is expected to increase by approximately 352.01 million yuan compared to the same period last year [2] - This represents a year-on-year growth of about 325.97% [2]